A drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's and other forms of dementia. That's the result of a study in which the benefit was so clear, the trial was ...
- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line results from the Phase 2 RADIANT study of remlifanserin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results